BNR Burning Rock Biotech Limited
Price Chart
Executive Summary
Burning Rock Biotech reported stable Q4 2025 revenue of $18.1 million with a 10.2% increase in gross profit and a significant 35.5% decline in operating expenses, leading to a 81% reduction in net loss year-over-year. Full-year 2025 revenue grew 4.6% to $77.2 million, driven by a 34.5% increase in pharma R&D services, while gross margin expanded to 74.7% and operating expenses fell 36.4%.
Key Financial Metrics
Actionable Insight
The significant reduction in losses and operating expenses, combined with margin expansion and growth in high-margin pharma R&D, suggests Burning Rock is executing a successful turnaround. Traders should monitor sustainability of cost controls and whether revenue growth accelerates in 2026.
Key Facts
- Q4 2025 revenue was $18.1 million (RMB126.3M), flat YoY, but gross profit rose 10.2% to $14.1 million with gross margin improving to 78.0% from 71.0%.
- Operating expenses dropped 35.5% YoY to $15.8 million, driven by cost controls and reorganization, leading to net loss narrowing to $2.2 million from $81.3 million in Q4 2024.
- Full-year 2025 revenue increased 4.6% to $77.2 million (RMB539.6M), with pharma R&D revenue surging 34.5% to $22.2 million.
- Gross margin improved to 74.7% in 2025 from 70.3% in 2024, and operating expenses fell 36.4% to $65.5 million.
- Net loss for 2025 was $7.9 million, down 84% from $346.6 million in 2024.
- Cash balance stood at $68.8 million as of December 31, 2025.
Financial Impact
Operating expenses reduced by $262.2 million annually, net loss improved by $291.3 million year-over-year, and gross margin expanded 440 bps.
Risk Factors
- Revenue remains flat in the near term, with central lab business declining 8.9% for the year.
- Pharma R&D revenue is project-based and lumpy, creating potential volatility.
- Company remains unprofitable on a GAAP basis despite progress.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254486 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 28, 2026
22d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Mar 12, 2026
9w ago
|
Press Release
| $22.85 $15.85 | ▼ −30.66% | ▼ −32.63% | $16.70 (−26.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access